April 2018 – World Premiere of “JFK The Last Speech”
I am delighted to announce the world premiere of “JFK. The Last Speech.” Five Amherst classmates —Neil Bicknell, the executive producer, and four other classmates and I as associate producers — had the privilege of working with producer-director Bestor Cram and Northern Light Productions to make this documentary. The film addresses the relevance of the JFK’s last speech at the time and the impact that it made in the lives of those who were there. I hope you enjoy it and ask your local PBS to air it!
“JFK The Last Speech” explores the dramatic relationship between two seminal Americans—President John F. Kennedy and the poet Robert Frost—which reached its tragic climax in a surprising encounter with Soviet Premier Nikita Khrushchev at the height of the Cold War.
Frost, a professor at Amherst, had “said” a poem at Kennedy’s inauguration, and John F Kennedy spoke at Amherst College in 1963 for the dedication of the new Robert Frost Library. JFK took the opportunity to address the future leaders in the audience – not just about poetry but about power and impact – and it has been called the “most majestic” speech of his career. He was assassinated just weeks later. However, few people knew the story behind the speech and the connection between John F. Kennedy and Robert Frost. The film addresses both this story and how the speech altered the lives of a group of Amherst college classmates who witnessed this compelling address.
“The men who create power make an indispensable contribution to a nation’s greatness. But the men who question power make a contribution just as indispensable – for they determine whether we use power or power uses us.” John F. Kennedy, delivered at Amherst College October 26, 1963
For more information about the event or to watch the trailer, please visit www.jfkthelastspeech.com.
Roger Mills is also the co-editor of a companion book, The Last Speech, available in late June, 2018.
April 2018 – “Don’t Take Candy From Strangers: 3 Warnings About Right To Try”
Drug safety issues often do not surface until late-phase trials expose larger and larger populations of patients, from one or two hundred in Phase 2 to several hundred or even thousands in Phase 3, with exposure over longer and longer periods, going incrementally from days to many months. In early stages, clinical development programs are just beginning to understand the potential safety issues of a new drug. Read the full article here.
January 2018 – “What’s Behind the Gender And Ethnicity Imbalance In Clinical Trials?”
Trialists must navigate between the powerful social initiatives favoring racial and gender “equality” and the possibility that drug and device efficacy and safety may differ by gender and ethnicity. Read the full article here.
December 2017 – “CRS Lawsuit: Does FDA Guidance Require More Clarity?”
No one can predict the outcome of the CRS lawsuit. However, given the clarity of the FDA’s guidance for patients and investigators and the large number of patients involved in clinical trials, I don’t think CRS can present a convincing argument that revision of the informed consent guidance is required or that such revision would somehow impact the small percentage of patients who, sadly, experience treatment-related mortality in clinical trials.
Read the full article on Clinical Leader here.
October 2017 – “Plan Ahead To Mitigate Post-Study Conflicts”
The message to the clinical research community is clear. Plan ahead. In almost all cases, the project is not complete until you have communicated the results in the peer-reviewed scientific literature. You are doing important work, and you must plan to present your data in a way that will enhance its credibility.
Read the full article on Clinical Leader here.
June 2017 – Nesiritide a 2016 Foreword INDIES bronze winner for Science
Nesiritide won the Indies Bronze in “Science” category (adult non-fiction science). “After Foreword’s top three editors narrowed the entrants down to finalists, our panel of over 150 judges, made up of librarians and booksellers chosen for their interest or expertise in their particular field, read every page. The judges’ feedback and ratings brought us our winners, which represent the best books from indie publishing, and those of particular interest to the very people who recommend books to patrons and consumers. Being an INDIES winner is no small feat–particularly this year when there was a record number of entries.”
List of winners: https://awards.forewordreviews.com/winners/2016/science/
March 2017 – Nesiritide a 2016 INDIES Book of the Year Finalist
Nesiritide was named 2016 Forward INDIES Book of the Year Finalist in the Science category. As part of their mission to discover, review, and share the best books from small, university, and indie publishers (and authors), independent media company Foreword Reviews hosts its annual awards program each year. Finalists represent the best books published in 2016, and submitted to Foreword Reviews for award consideration, and were narrowed down by Foreword’s editors from over 2,200 individual titles spread across 65 categories.
INDIES finalists are moved on to final judging by an expert panel of librarians and booksellers curated specifically for each genre and who will determine the books who will be named Foreword INDIES Book of the Year Award winners. Winners in each genre will be announced during the 2017 American Library Association Annual Conference in Chicago on June 24, 2017.
List of finalists: https://awards.forewordreviews.com/finalists/2016/
March 2017 – Nesiritide Reviewed by BlueInk
“Mills works hard to make the arcane accessible… This is an important story well worth reading for scholars and those with a strong interest in the topic as Mills pulls back the curtain to a mostly hidden world.”
February 2017 – Nesiritide Featured in Amherst Magazine
Nesiritide received a brief mention in the winter Amherst magazine. Short Takes is a listing of new books and other creative endeavors by Amherst alumni and professors: